Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome

World Journal of Gastroenterology

Volumn 15, Issue 48, 2009, Pages 6068-6074

  Kajander, Kajsa ^a,b   Myllyluoma, Eveliina ^a,b   Kyrönpalo, Sinikka ^c   Rasmussen, Martin ^c   Sipponen, Pentti ^d   Mattila, Ismo ^e   Seppänen Laakso, Tuulikki ^e   Vapaatalo, Heikki ^a   Oreşiç, Matej ^e   Korpela, Riitta ^a,b,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b VALIO LTD   (Finland)

^c Tampere City Hospital   (Finland)

^d JORVI HOSPITAL   (Finland)

^e VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^f FOUNDATION FOR NUTRITION RESEARCH   (Finland)

Author keywords

Functional gastrointestinal diseases; Histopathology; Irritable bowel syndrome

Indexed keywords

CERAMIDE; DIACYLGLYCEROL; GLYCOSPHINGOLIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IRRITABLE COLON; LIPIDOMICS; MALE; METABOLOMICS; PATHOPHYSIOLOGY; UPREGULATION;

EID: 75349109603     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.6068     Document Type: Article

References (45)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-2131
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491
3. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457
4. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Saperas E, Malagelada JR. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209
5. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702
6. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37
7. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311
8. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
9. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920
10. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783
11. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979
12. Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL, Han SP. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007; 13: 6041-6047
13. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998; 42: 42-46
14. Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, Spiller RC. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 349-357
15. Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, Moses PL. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664
16. Orešič M, Vidal-Puig A, Hänninen V. Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev Mol Diagn 2006; 6: 575-585
17. Schnackenberg LK, Beger RD. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics 2006; 7: 1077-1086
18. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2: II43-II47
19. Katajamaa M, Orešič M. Processing methods for differential analysis of LC/MS profile data. BMC Bioinformatics 2005; 6: 179
20. Welthagen W, Shellie RA, Spranger J, Ristow M, Zimmermann R, Fiehn O. Comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry (GC x GC-TOF) for high resolution metabolomics: biomarker discovery on spleen tissue extracts of obese NZO compared to lean C57BL/6 mice. Metabolomics 2005; 1: 65-73
21. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440-9445
22. Yetukuri L, Katajamaa M, Medina-Gomez G, Seppänen-Laakso T, Vidal-Puig A, Orešič M. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007; 1: 12
23. Schlotterbeck G, Ross A, Dieterle F, Senn H. Metabolic profiling technologies for biomarker discovery in biomedicine and drug development. Pharmacogenomics 2006; 7: 1055-1075
24. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, Wilson ID, Wang Y. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007; 6: 546-551
25. Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, Kaprio J, Orešič M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects - a monozygotic twin study. PLoS One 2007; 2: e218
26. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, Niesporek S, Konsgen D, Dietel M, Fiehn O. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006; 66: 10795-10804
27. Park KA, Vasko MR. Lipid mediators of sensitivity in sensory neurons. Trends Pharmacol Sci 2005; 26: 571-577
28. Malan TP Jr, Porreca F. Lipid mediators regulating pain sensitivity. Prostaglandins Other Lipid Mediat 2005; 77: 123-130
29. Minami T, Tojo H, Shinomura Y, Matsuzawa Y, Okamoto M. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut 1994; 35: 1593-1598
30. Haapamäki MM, Grönroos JM, Nurmi H, Irjala K, Alanen KA, Nevalainen TJ. Phospholipase A2 in serum and colonic mucosa in ulcerative colitis. Scand J Clin Lab Invest 1999; 59: 279-287
31. Tagesson C, Franzen L, Dahl G, Weström B. Lysophosphatidylcholine increases rat ileal permeability to macromolecules. Gut 1985; 26: 369-377
32. Otamiri T, Sjödahl R, Tagesson C. Lysophosphatidylcholine potentiates the increase in mucosal permeability after smallintestinal ischaemia. Scand J Gastroenterol 1986; 21: 1131-1136
33. Karlqvist PA, Franzen L, Sjödahl R, Tagesson C. Lysophosphatidylcholine and taurodeoxycholate increase stomach permeability to different-sized molecules. Scand J Gastroenterol 1986; 21: 1039-1045
34. Sawai T, Lampman R, Hua Y, Segura B, Drongowski RA, Coran AG, Harmon CM. Lysophosphatidylcholine alters enterocyte monolayer permeability via a protein kinase C/ Ca2+ mechanism. Pediatr Surg Int 2002; 18: 591-594
35. Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 545-552
36. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006; 12: RA5-R16
37. Sakata A, Yasuda K, Ochiai T, Shimeno H, Hikishima S, Yokomatsu T, Shibuya S, Soeda S. Inhibition of lipopolysaccharide-induced release of interleukin-8 from intestinal epithelial cells by SMA, a novel inhibitor of sphingomyelinase and its therapeutic effect on dextran sulphate sodium-induced colitis in mice. Cell Immunol 2007; 245: 24-31
38. Homaidan FR, El-Sabban ME, Chakroun I, El-Sibai M, Dbaibo GS. IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells. Mediators Inflamm 2002; 11: 39-45
39. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45: 42-72
40. Andrieu-Abadie N, Gouaze V, Salvayre R, Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic Biol Med 2001; 31: 717-728
41. Assimakopoulos SF, Vagianos CE, Patsoukis N, Georgiou C, Nikolopoulou V, Scopa CD. Evidence for intestinal oxidative stress in obstructive jaundice-induced gut barrier dysfunction in rats. Acta Physiol Scand 2004; 180: 177-185
42. Martin FP, Verdu EF, Wang Y, Dumas ME, Yap IK, Cloarec O, Bergonzelli GE, Corthesy-Theulaz I, Kochhar S, Holmes E, Lindon JC, Collins SM, Nicholson JK. Transgenomic metabolic interactions in a mouse disease model: interactions of Trichinella spiralis infection with dietary Lactobacillus paracasei supplementation. J Proteome Res 2006; 5: 2185-2193
43. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382
44. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33
45. Clark JF. The creatine kinase system in smooth muscle. Mol Cell Biochem 1994; 133-134: 221-232